How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy

1.

Lianidou, E. S. (2014). Circulating tumor cell isolation: A marathon race worth running. Clinical Chemistry, 60(2), 287–289. https://doi.org/10.1373/clinchem.2013.216010CrossRefPubMed

2.

TR, A. (1869). A case of cancer in which cells similar to those in the tumours were seen in the blood after death. The Medical Journal of Australia, 14, 146–147.

3.

Hong, Y., Fang, F., & Zhang, Q. (2016). Circulating tumor cell clusters: What we know and what we expect (review). International Journal of Oncology, 49(6), 2206–2216. https://doi.org/10.3892/ijo.2016.3747CrossRefPubMedPubMedCentral

4.

Dianat-Moghadam, H., Azizi, M., Eslami-S, Z., Cortés-Hernández, L. E., Heidarifard, M., Nouri, M., & Alix-Panabières, C. (2020). The role of circulating tumor cells in the metastatic cascade: Biology, technical challenges, and clinical relevance. Cancers, 12(4). https://doi.org/10.3390/cancers12040867

5.

Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., Yu, M., Pely, A., Engstrom, A., Zhu, H., & Brannigan, B. W. (2014). Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell, 158(5), 1110–1122. https://doi.org/10.1016/j.cell.2014.07.013CrossRefPubMedPubMedCentral

6.

Brandt, B., Junker, R., Griwatz, C., Heidl, S., Brinkmann, O., Semjonow, A., Assmann, G., & Zänker, K. S. (1996). Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Research, 56(20), 4556–4561. https://www.ncbi.nlm.nih.gov/pubmed/8840959PubMed

7.

Peeters, D. J., Brouwer, A., Van den Eynden, G. G., Rutten, A., Onstenk, W., Sieuwerts, A. M., Van Laere, S. J., Huget, P., Pauwels, P., Peeters, M., & Vermeulen, P. B. (2015). Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. Cancer Letters, 356(2), 872–879. https://doi.org/10.1016/j.canlet.2014.10.039CrossRefPubMed

8.

Chen, H., Cao, B., Sun, B., Cao, Y., Yang, K., & Lin, Y. S. (2018). Author correction: Highly-sensitive capture of circulating tumor cells using micro-ellipse filters. Scientific Reports, 8(1), 5269. https://doi.org/10.1038/s41598-018-22955-wCrossRefPubMedPubMedCentral

9.

Zeinali, M., Lee, M., Nadhan, A., Mathur, A., Hedman, C., Lin, E., Harouaka, R., Wicha, M. S., Zhao, L., Palanisamy, N., & Hafner, M. (2020). High-throughput label-free isolation of heterogeneous circulating tumor cells and CTC clusters from non-small-cell lung cancer patients. Cancers, 12. https://doi.org/10.3390/cancers12010127

10.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, "Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches," Journal of Thoracic Oncology, vol. 7, no. 2, pp. 306-315, Feb 2012. https://doi.org/10.1097/JTO.0b013e31823c5c16.

11.

Wendel, M., Bazhenova, L., Boshuizen, R., Kolatkar, A., Honnatti, M., Cho, E. H., Marrinucci, D., Sandhu, A., Perricone, A., Thistlethwaite, P., & Bethel, K. (2012). Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: A glimpse into lung cancer biology. Physical Biology, 9(1), 016005. https://doi.org/10.1088/1478-3967/9/1/016005CrossRefPubMedPubMedCentral

12.

Hou, J. M., Krebs, M. G., Lancashire, L., Sloane, R., Backen, A., Swain, R. K., Priest, L. J., Greystoke, A., Zhou, C., Morris, K., & Ward, T. (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. Journal of Clinical Oncology, 30(5), 525–532. https://doi.org/10.1200/JCO.2010.33.3716CrossRefPubMed

13.

Denes, V., Lakk, M., Makarovskiy, A., Jakso, P., Szappanos, S., Graf, L., Mandel, L., Karadi, I., & Geck, P. (2015). Metastasis blood test by flow cytometry: In vivo cancer spheroids and the role of hypoxia. International Journal of Cancer, 136(7), 1528–1536. https://doi.org/10.1002/ijc.29155CrossRefPubMed

14.

Sawabata, N., Nakamura, T., Kawaguchi, T., Watanabe, T., Ouji, N. S., Ito, T., & Taniguchi, S. (2020). Circulating tumor cells detected only after surgery for non-small cell lung cancer: Is it a predictor of recurrence? Journal of Thoracic Disease, 12(9), 4623–4632. https://doi.org/10.21037/jtd-20-1636CrossRefPubMedPubMedCentral

15.

Giesing, M., Suchy, B., Driesel, G., & Molitor, D. (2010). Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy. BJU International, 105(7), 1000–1010. https://doi.org/10.1111/j.1464-410X.2009.08920.xCrossRefPubMed

16.

Cho, E. H., Wendel, M., Luttgen, M., Yoshioka, C., Marrinucci, D., Lazar, D., Schram, E., Nieva, J., Bazhenova, L., Morgan, A., & Ko, A. H. (2012). Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Physical Biology, 9(1), 016001. https://doi.org/10.1088/1478-3975/9/1/016001CrossRefPubMedPubMedCentral

17.

Friedlander, T. W., Ngo, V. T., Dong, H., Premasekharan, G., Weinberg, V., Doty, S., Zhao, Q., Gilbert, E. G., Ryan, C. J., Chen, W. T., & Paris, P. L. (2014). Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. International Journal of Cancer, 134(10), 2284–2293. https://doi.org/10.1002/ijc.28561CrossRefPubMed

18.

Wang, C., Zhang, Z., Chong, W., Luo, R., Myers, R. E., Gu, J., Lin, J., Wei, Q., Li, B., Rebbeck, T. R., & Lu-Yao, G. (2021). Improved prognostic stratification using circulating tumor cell clusters in patients with metastatic castration-resistant prostate cancer. Cancers, 13, 268. https://doi.org/10.3390/cancers13020268CrossRefPubMedPubMedCentral

19.

Sarioglu, A. F., Aceto, N., Kojic, N., Donaldson, M. C., Zeinali, M., Hamza, B., Engstrom, A., Zhu, H., Sundaresan, T. K., Miyamoto, D. T., & Luo, X. (2015). A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nature Methods, 12(7), 685–691. https://doi.org/10.1038/nmeth.3404CrossRefPubMedPubMedCentral

20.

Mu, Z., Wang, C., Ye, Z., Austin, L., Civan, J., Hyslop, T., Palazzo, J. P., Jaslow, R., Li, B., Myers, R. E., & Jiang, J. (2015). Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Research and Treatment, 154(3), 563–571. https://doi.org/10.1007/s10549-015-3636-4CrossRefPubMed

21.

Jansson, S., Bendahl, P. O., Larsson, A. M., Aaltonen, K. E., & Ryden, L. (2016). Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer, 16, 433. https://doi.org/10.1186/s12885-016-2406-yCrossRefPubMedPubMedCentral

22.

Zhuang, J., Liang, S., Chen, L., Yang, F., Huo, Q., Wu, M., Zhang, Y., & Xie, N. (2021). Utilizing a high-throughput microdevice to study breast tumor cells clustering and metastasis. Analytica Chimica Acta, 1151, 338222. https://doi.org/10.1016/j.aca.2021.338222CrossRefPubMed

23.

Molnar, B., Ladanyi, A., Tanko, L., Sreter, L., & Tulassay, Z. (2001). Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clinical Cancer Research, 7(12), 4080–4085. https://www.ncbi.nlm.nih.gov/pubmed/11751505PubMed

24.

Mohamed, H., Murray, M., Turner, J. N., & Caggana, M. (2009). Isolation of tumor cells using size and deformation. Journal of Chromatography. A, 1216(47), 8289–8295. https://doi.org/10.1016/j.chroma.2009.05.036CrossRefPubMed

25.

Chang, M. C., Chang, Y. T., Chen, J. Y., Jeng, Y. M., Yang, C. Y., Tien, Y. W., Yang, S. H., Chen, H. L., Liang, T. Y., Wang, C. F., & Lee, E. Y. (2016). Clinical significance of circulating tumor microemboli as a prognostic marker in patients with pancreatic ductal adenocarcinoma. Clinical Chemistry, 62(3), 505–513. https://doi.org/10.1373/clinchem.2015.248260CrossRefPubMed

26.

Long, E., Ilie, M., Bence, C., Butori, C., Selva, E., Lalvée, S., Bonnetaud, C., Poissonnet, G., Lacour, J. P., Bahadoran, P., & Brest, P. (2016). High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness. Cancer Medicine, 5(6), 1022–1030. https://doi.org/10.1002/cam4.661CrossRefPubMedPubMedCentral

27.

Xiang, A., Xue, M., Ren, F., Wang, L., Ye, Z., Li, D., Ji, Q., Ji, G., & Lu, Z. (2020). High throughput and continuous flow isolation of rare circulating tumor cells and clusters in gastric cancer from human whole blood samples using electromagnetic vibration based filtration. Oncology Reports, 43(6), 1975–1985. https://doi.org/10.3892/or.2020.7567CrossRefPubMedPubMedCentral

28.

Watanabe, S. (1954). The metastasizability of tumor cells. Cancer, 7(2), 215–223. https://doi.org/10.1002/1097-0142(195403)7:2<215::aid-cncr2820070203>3.0.co;2-6CrossRefPubMed

29.

Thompson, S. C. (1974). The colony forming efficiency of single cells and cell aggregates from a spontaneous mouse mammary tumour using the lung colony assay. British Journal of Cancer, 30(4), 332–336. https://doi.org/10.1038/bjc.1974.201CrossRefPubMedPubMedCentral

30.

Topal, B., Roskams, T., Fevery, J., & Penninckx, F. (2003). Aggregated colon cancer cells have a higher metastatic efficiency in the liver compared with nonaggregated cells: An experimental study. The Journal of Surgical Research, 112(1), 31–37. https://doi.org/10.1016/s0022-4804(03)00140-9CrossRefPubMed

31.

I. J. Fidler, "The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis," European Journal of Cancer, vol. 9, no. 3, pp. 223-227, Mar 1973. https://doi.org/10.1016/s0014-2964(73)80022-2.

32.

Herath, S., Razavi Bazaz, S., Monkman, J., Ebrahimi Warkiani, M., Richard, D., O’Byrne, K., & Kulasinghe, A. (2020). Circulating tumor cell clusters: Insights into tumour dissemination and metastasis. Expert Review of Molecular Diagnostics, 20(11), 1139–1147. https://doi.org/10.1080/14737159.2020.1846523CrossRefPubMed

33.

Costa, C., Muinelo-Romay, L., Cebey-López, V., Pereira-Veiga, T., Martínez-Pena, I., Abreu, M., Abalo, A., Lago-Lestón, R. M., Abuín, C., Palacios, P., & Cueva, J. (2020). Analysis of a real-world cohort of metastatic breast cancer patients shows circulating tumor cell clusters (CTC-clusters) as predictors of patient outcomes. Cancers, 12(5). https://doi.org/10.3390/cancers12051111

34.

Xie N, Hu Z, Tian C, Xiao H, Liu L, Yang X, Li J, Wu H, Lu J, Gao J, Hu X, "In vivo detection of CTC and CTC plakoglobin status helps predict prognosis in patients with metastatic breast cancer," Pathology Oncology Research, vol. 26, no. 4, pp. 2435-2442, Oct 2020. https://doi.org/10.1007/s12253-020-00847-7.

35.

Amintas, S., Bedel, A., Moreau-Gaudry, F., Boutin, J., Buscail, L., Merlio, J. P., Vendrely, V., Dabernat, S., & Buscail, E. (2020). Circulating tumor cell clusters: United we stand divided we fall. International Journal of Molecular Sciences, 21(7). https://doi.org/10.3390/ijms21072653

36.

Hou, J. M., Krebs, M., Ward, T., Sloane, R., Priest, L., Hughes, A., Clack, G., Ranson, M., Blackhall, F., & Dive, C. (2011). Circulating tumor cells as a window on metastasis biology in lung cancer. The American Journal of Pathology, 178(3), 989–996. https://doi.org/10.1016/j.ajpath.2010.12.003CrossRefPubMedPubMedCentral

37.

Fang, C., & Kang, Y. (2020). Cellular plasticity in bone metastasis. Bone, 158, 115693. https://doi.org/10.1016/j.bone.2020.115693CrossRefPubMedPubMedCentral

38.

Maeshiro, M., Shinriki, S., Liu, R., Nakachi, Y., Komohara, Y., Fujiwara, Y., Ohtsubo, K., Yoshida, R., Iwamoto, K., Nakayama, H., & Matsui, H. (2021). Colonization of distant organs by tumor cells generating circulating homotypic clusters adaptive to fluid shear stress. Scientific Reports, 11(1), 6150. https://doi.org/10.1038/s41598-021-85743-zCrossRefPubMedPubMedCentral

39.

Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, Gorin MA, Verdone JE, Pienta KJ, Bader JS, Ewald AJ., "Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters," Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 7, pp. E854-E863, Feb 16 2016. https://doi.org/10.1073/pnas.1508541113.

40.

Aiello, N. M., Maddipati, R., Norgard, R. J., Balli, D., Li, J., Yuan, S., Yamazoe, T., Black, T., Sahmoud, A., Furth, E. E., & Bar-Sagi, D. (2018). EMT subtype influences epithelial plasticity and mode of cell migration. Developmental Cell, 45(6), 681–695. https://doi.org/10.1016/j.devcel.2018.05.027CrossRefPubMedPubMedCentral

41.

Cheung, K. J., Gabrielson, E., Werb, Z., & Ewald, A. J. (2013). Collective invasion in breast cancer requires a conserved basal epithelial program. Cell, 155(7), 1639–1651. https://doi.org/10.1016/j.cell.2013.11.029CrossRefPubMedPubMedCentral

42.

Cheung, K. J., & Ewald, A. J. (2016). A collective route to metastasis: Seeding by tumor cell clusters. Science, 352(6282), 167–169. https://doi.org/10.1126/science.aaf6546CrossRefPubMedPubMedCentral

43.

Gkountela, S., Castro-Giner, F., Szczerba, B. M., Vetter, M., Landin, J., Scherrer, R., Krol, I., Scheidmann, M. C., Beisel, C., Stirnimann, C. U., & Kurzeder, C. (2019). Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell, 176(1-2), 98–112. https://doi.org/10.1016/j.cell.2018.11.046CrossRefPubMedPubMedCentral

44.

Liu, X., Taftaf, R., Kawaguchi, M., Chang, Y. F., Chen, W., Entenberg, D., Zhang, Y., Gerratana, L., Huang, S., Patel, D. B., & Tsui, E. (2019). Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discovery, 9(1), 96–113. https://doi.org/10.1158/2159-8290.CD-18-0065CrossRefPubMed

45.

B. Cieply, C. Koontz, and S. M. Frisch, "CD44S-hyaluronan interactions protect cells resulting from EMT against anoikis," Matrix Biology, vol. 48, pp. 55-65, Oct 2015. https://doi.org/10.1016/j.matbio.2015.04.010.

46.

Hurtado, P., Martinez-Pena, I., & Pineiro, R. (2020). Dangerous liaisons: Circulating tumor cells (CTCs) and cancer-associated fibroblasts (CAFs). Cancers, 12(10), 2861. https://doi.org/10.3390/cancers12102861CrossRefPubMedPubMedCentral

47.

Duda, D. G., Duyverman, A. M., Kohno, M., Snuderl, M., Steller, E. J., Fukumura, D., & Jain, R. K. (2010). Malignant cells facilitate lung metastasis by bringing their own soil. Proceedings of the National Academy of Sciences of the United States of America, 107(50), 21677–21682. https://doi.org/10.1073/pnas.1016234107CrossRefPubMedPubMedCentral

48.

Luo, Q., Wang, C., Peng, B., Pu, X., Cai, L., Liao, H., Chen, K., Zhang, C., Cheng, Y., & Pan, M. (2020). Circulating tumor-cell-associated white blood cell clusters in peripheral blood indicate poor prognosis in patients with hepatocellular carcinoma. Frontiers in Oncology, 10, 1758. https://doi.org/10.3389/fonc.2020.01758CrossRefPubMedPubMedCentral

49.

Kamyabi, N., Huang, J., Lee, J. J., Bernard, V., Semaan, A., Stephens, B., Hurd, M. W., Vanapalli, S. A., Maitra, A., & Guerrero, P. A. (2019). A microfluidic device for label-free isolation of tumor cell clusters from unprocessed blood samples. Biomicrofluidics, 13(4), 044111. https://doi.org/10.1063/1.5111888CrossRefPubMedPubMedCentral

50.

Szczerba, B. M., Castro-Giner, F., Vetter, M., Krol, I., Gkountela, S., Landin, J., Scheidmann, M. C., Donato, C., Scherrer, R., Singer, J., & Beisel, C. (2019). Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 566(7745), 553–557. https://doi.org/10.1038/s41586-019-0915-yCrossRefPubMed

51.

Egan, K., Cooke, N., & Kenny, D. (2014). Living in shear: Platelets protect cancer cells from shear induced damage. Clinical & Experimental Metastasis, 31(6), 697–704. https://doi.org/10.1007/s10585-014-9660-7CrossRef

52.

Biggerstaff, J. P., Seth, N., Amirkhosravi, A., Amaya, M., Fogarty, S., Meyer, T. V., Siddiqui, F., & Francis, J. L. (1999). Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clinical & Experimental Metastasis, 17(8), 723–730. https://doi.org/10.1023/a:1006763827882CrossRef

53.

Akolkar, D., Patil, D., Crook, T., Limaye, S., Page, R., Datta, V., Patil, R., Sims, C., Ranade, A., Fulmali, P., & Fulmali, P. (2020). Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. International Journal of Cancer, 146(12), 3485–3494. https://doi.org/10.1002/ijc.32815CrossRefPubMed

54.

Coban, B., Bergonzini, C., Zweemer, A. J. M., & Danen, E. H. J. (2021). Metastasis: Crosstalk between tissue mechanics and tumour cell plasticity. British Journal of Cancer, 124(1), 49–57. https://doi.org/10.1038/s41416-020-01150-7CrossRefPubMed

55.

Genna, A., Vanwynsberghe, A. M., Villard, A. V., Pottier, C., Ancel, J., Polette, M., & Gilles, C. (2020). EMT-associated heterogeneity in circulating tumor cells: Sticky friends on the road to metastasis. Cancers, 12(6). https://doi.org/10.3390/cancers12061632

56.

Wei, R. R., Sun, D. N., Yang, H., Yan, J., Zhang, X., Zheng, X. L., Fu, X. H., Geng, M. Y., Huang, X., & Ding, J. (2018). CTC clusters induced by heparanase enhance breast cancer metastasis. Acta Pharmacologica Sinica, 39(8), 1326–1337. https://doi.org/10.1038/aps.2017.189CrossRefPubMedPubMedCentral

57.

Glinsky, V. V., Glinsky, G. V., Glinskii, O. V., Huxley, V. H., Turk, J. R., Mossine, V. V., Deutscher, S. L., Pienta, K. J., & Quinn, T. P. (2003). Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Research, 63(13), 3805–3811 https://www.ncbi.nlm.nih.gov/pubmed/12839977.PubMed

58.

Orr, F. W., & Wang, H. H. (2001). Tumor cell interactions with the microvasculature: A rate-limiting step in metastasis. Surgical Oncology Clinics of North America, 10(2), 357–381. https://www.ncbi.nlm.nih.gov/pubmed/11382592CrossRefPubMed

59.

Maddipati, R., & Stanger, B. Z. (2015). Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discovery, 5(10), 1086–1097. https://doi.org/10.1158/2159-8290.CD-15-0120CrossRefPubMedPubMedCentral

60.

Chapnick, D. A., & Liu, X. (2014). Leader cell positioning drives wound-directed collective migration in TGFbeta-stimulated epithelial sheets. Molecular Biology of the Cell, 25(10), 1586–1593. https://doi.org/10.1091/mbc.E14-01-0697CrossRefPubMedPubMedCentral

61.

Li, C. F., Chen, J. Y., Ho, Y. H., Hsu, W. H., Wu, L. C., Lan, H. Y., Hsu, D. S., Tai, S. K., Chang, Y. C., & Yang, M. H. (2019). Snail-induced claudin-11 prompts collective migration for tumour progression. Nature Cell Biology, 21(2), 251–262. https://doi.org/10.1038/s41556-018-0268-zCrossRefPubMed

62.

Lecharpentier, A., Vielh, P., Perez-Moreno, P., Planchard, D., Soria, J. C., & Farace, F. (2011). Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. British Journal of Cancer, 105(9), 1338–1341. https://doi.org/10.1038/bjc.2011.405CrossRefPubMedPubMedCentral

63.

Satelli, A., Mitra, A., Brownlee, Z., Xia, X., Bellister, S., Overman, M. J., Kopetz, S., Ellis, L. M., Meng, Q. H., & Li, S. (2015). Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clinical Cancer Research, 21(4), 899–906. https://doi.org/10.1158/1078-0432.CCR-14-0894CrossRefPubMed

64.

Ring, A., Spataro, M., Wicki, A., & Aceto, N. (2022). Clinical and biological aspects of disseminated tumor cells and dormancy in breast cancer. Frontiers in Cell and Development Biology, 10, 929893. https://doi.org/10.3389/fcell.2022.929893CrossRef

65.

Sharma, V. P., Tang, B., Wang, Y., Duran, C. L., Karagiannis, G. S., Xue, E. A., Entenberg, D., Borriello, L., Coste, A., Eddy, R. J., & Kim, G. (2021). Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination. Nature Communications, 12(1), 7300. https://doi.org/10.1038/s41467-021-27308-2CrossRefPubMedPubMedCentral

66.

Phillips, K. G., Lee, A. M., Tormoen, G. W., Rigg, R. A., Kolatkar, A., Luttgen, M., Bethel, K., Bazhenova, L., Kuhn, P., Newton, P., & OJ, M. C. (2015). The thrombotic potential of circulating tumor microemboli: Computational modeling of circulating tumor cell-induced coagulation. American Journal of Physiology. Cell Physiology, 308(3), C229–C236. https://doi.org/10.1152/ajpcell.00315.2014CrossRefPubMed

67.

Kallergi, G., Konstantinidis, G., Markomanolaki, H., Papadaki, M. A., Mavroudis, D., Stournaras, C., Georgoulias, V., & Agelaki, S. (2013). Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Molecular Cancer Therapeutics, 12(9), 1886–1895. https://doi.org/10.1158/1535-7163.MCT-12-1167CrossRefPubMed

68.

Zhao, Q., Barclay, M., Hilkens, J., Guo, X., Barrow, H., Rhodes, J. M., & Yu, L. G. (2010). Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Molecular Cancer, 9, 154. https://doi.org/10.1186/1476-4598-9-154CrossRefPubMedPubMedCentral

69.

Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., & Weinberg, R. A. (2008). Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Research, 68(10), 3645–3654. https://doi.org/10.1158/0008-5472.CAN-07-2938CrossRefPubMed

70.

Charpentier, M., & Martin, S. (2013). Interplay of stem cell characteristics, EMT, and microtentacles in circulating breast tumor cells. Cancers (Basel), 5(4), 1545–1565. https://doi.org/10.3390/cancers5041545CrossRefPubMed

71.

Whipple, R. A., Balzer, E. M., Cho, E. H., Matrone, M. A., Yoon, J. R., & Martin, S. S. (2008). Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Research, 68(14), 5678–5688. https://doi.org/10.1158/0008-5472.CAN-07-6589CrossRefPubMedPubMedCentral

72.

Kallergi, G., Aggouraki, D., Zacharopoulou, N., Stournaras, C., Georgoulias, V., & Martin, S. S. (2018). Evaluation of alpha-tubulin, detyrosinated alpha-tubulin, and vimentin in CTCs: Identification of the interaction between CTCs and blood cells through cytoskeletal elements. Breast Cancer Research, 20(1), 67. https://doi.org/10.1186/s13058-018-0993-zCrossRefPubMedPubMedCentral

73.

Adams, D. L., Martin, S. S., Alpaugh, R. K., Charpentier, M., Tsai, S., Bergan, R. C., Ogden, I. M., Catalona, W., Chumsri, S., Tang, C. M., & Cristofanilli, M. (2014). Circulating giant macrophages as a potential biomarker of solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 111(9), 3514–3519. https://doi.org/10.1073/pnas.1320198111CrossRefPubMedPubMedCentral

74.

Au, S. H., Storey, B. D., Moore, J. C., Tang, Q., Chen, Y. L., Javaid, S., Sarioglu, A. F., Sullivan, R., Madden, M. W., O’Keefe, R., & Haber, D. A. (2016). Clusters of circulating tumor cells traverse capillary-sized vessels. Proceedings of the National Academy of Sciences of the United States of America, 113(18), 4947–4952. https://doi.org/10.1073/pnas.1524448113CrossRefPubMedPubMedCentral

75.

King, M. R., Phillips, K. G., Mitrugno, A., Lee, T. R., de Guillebon, A. M., Chandrasekaran, S., MJ, M. G., Carr, R. T., Baker-Groberg, S. M., Rigg, R. A., & Kolatkar, A. (2015). A physical sciences network characterization of circulating tumor cell aggregate transport. American Journal of Physiology. Cell Physiology, 308(10), C792–C802. https://doi.org/10.1152/ajpcell.00346.2014CrossRefPubMedPubMedCentral

76.

Geng, Y., Chandrasekaran, S., Hsu, J. W., Gidwani, M., Hughes, A. D., & King, M. R. (2013). Phenotypic switch in blood: Effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PLoS One, 8(1), e54959. https://doi.org/10.1371/journal.pone.0054959CrossRefPubMedPubMedCentral

77.

Yu, L. G., Andrews, N., Zhao, Q., McKean, D., Williams, J. F., Connor, L. J., Gerasimenko, O. V., Hilkens, J., Hirabayashi, J., Kasai, K., & Rhodes, J. M. (2007). Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. The Journal of Biological Chemistry, 282(1), 773–781. https://doi.org/10.1074/jbc.M606862200CrossRefPubMed

78.

Zhao, Q., Guo, X., Nash, G. B., Stone, P. C., Hilkens, J., Rhodes, J. M., & Yu, L. G. (2009). Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Research, 69(17), 6799–6806. https://doi.org/10.1158/0008-5472.CAN-09-1096CrossRefPubMedPubMedCentral

79.

Sharma, D., Brummel-Ziedins, K. E., Bouchard, B. A., & Holmes, C. E. (2014). Platelets in tumor progression: A host factor that offers multiple potential targets in the treatment of cancer. Journal of Cellular Physiology, 229(8), 1005–1015. https://doi.org/10.1002/jcp.24539CrossRefPubMed

80.

Kopp, H. G., Placke, T., & Salih, H. R. (2009). Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Research, 69(19), 7775–7783. https://doi.org/10.1158/0008-5472.CAN-09-2123CrossRefPubMed

81.

Lo, H. C., Xu, Z., Kim, I. S., Pingel, B., Aguirre, S., Kodali, S., Liu, J., Zhang, W., Muscarella, A. M., Hein, S. M., & Krupnick, A. S. (2020). Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis. Nat Cancer, 1, 709–722. https://doi.org/10.1038/s43018-020-0068-9CrossRefPubMed

82.

Harper, K. L., Sosa, M. S., Entenberg, D., Hosseini, H., Cheung, J. F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R. J., & Farias, E. F. (2016). Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature, 540(7634), 588–592. https://doi.org/10.1038/nature20609CrossRefPubMedPubMedCentral

83.

Albrengues, J., Shields, M. A., Ng, D., Park, C. G., Ambrico, A., Poindexter, M. E., Upadhyay, P., Uyeminami, D. L., Pommier, A., Küttner, V., & Bružas, E. (2018). Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science, 361(6409), eaao4227. https://doi.org/10.1126/science.aao4227CrossRefPubMedPubMedCentral

84.

Risson, E., Nobre, A. R., Maguer-Satta, V., & Aguirre-Ghiso, J. A. (2020). The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer, 1(7), 672–680. https://doi.org/10.1038/s43018-020-0088-5CrossRefPubMedPubMedCentral

85.

Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014). Mechanisms of disseminated cancer cell dormancy: An awakening field. Nature Reviews. Cancer, 14(9), 611–622. https://doi.org/10.1038/nrc3793CrossRefPubMedPubMedCentral

86.

Braun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, C. R., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., & Riethmüller, G. (2000). Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. The New England Journal of Medicine, 342(8), 525–533. https://doi.org/10.1056/NEJM200002243420801CrossRefPubMed

87.

Prunier, C., Baker, D., Ten Dijke, P., & Ritsma, L. (2019). TGF-beta family signaling pathways in cellular dormancy. Trends Cancer, 5(1), 66–78. https://doi.org/10.1016/j.trecan.2018.10.010CrossRefPubMed

88.

Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H. G., Schewe, D. M., & Aguirre-Ghiso, J. A. (2013). TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nature Cell Biology, 15(11), 1351–1361. https://doi.org/10.1038/ncb2861CrossRefPubMedPubMedCentral

89.

Yumoto, K., Eber, M. R., Wang, J., Cackowski, F. C., Decker, A. M., Lee, E., Nobre, A. R., Aguirre-Ghiso, J. A., Jung, Y., & Taichman, R. S. (2016). Axl is required for TGF-beta2-induced dormancy of prostate cancer cells in the bone marrow. Scientific Reports, 6, 36520. https://doi.org/10.1038/srep36520CrossRefPubMedPubMedCentral

90.

Axelrod, H. D., Valkenburg, K. C., Amend, S. R., Hicks, J. L., Parsana, P., Torga, G., AM, D. M., & Pienta, K. J. (2019). AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Molecular Cancer Research, 17(2), 356–369. https://doi.org/10.1158/1541-7786.MCR-18-0718CrossRefPubMed

91.

Taichman, R. S., Patel, L. R., Bedenis, R., Wang, J., Weidner, S., Schumann, T., Yumoto, K., Berry, J. E., Shiozawa, Y., & Pienta, K. J. (2013). GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One, 8(4), e61873. https://doi.org/10.1371/journal.pone.0061873CrossRefPubMedPubMedCentral

92.

Shiozawa, Y., Berry, J. E., Eber, M. R., Jung, Y., Yumoto, K., Cackowski, F. C., Yoon, H. J., Parsana, P., Mehra, R., Wang, J., & McGee, S. (2016). The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. Oncotarget, 7(27), 41217–41232. https://doi.org/10.18632/oncotarget.9251CrossRefPubMedPubMedCentral

93.

Johnson RW, Finger EC, Olcina MM, Vilalta M, Aguilera T, Miao Y, Merkel AR, Johnson JR, Sterling JA, Wu JY, Giaccia AJ, "Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow," Nature Cell Biology, vol. 18, no. 10, pp. 1078-1089, Oct 2016. https://doi.org/10.1038/ncb3408.

94.

Barkan, D., Kleinman, H., Simmons, J. L., Asmussen, H., Kamaraju, A. K., Hoenorhoff, M. J., Liu, Z. Y., Costes, S. V., Cho, E. H., Lockett, S., & Khanna, C. (2008). Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research, 68(15), 6241–6250. https://doi.org/10.1158/0008-5472.CAN-07-6849CrossRefPubMedPubMedCentral

95.

Shibue, T., & Weinberg, R. A. (2009). Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proceedings of the National Academy of Sciences of the United States of America, 106(25), 10290–10295. https://doi.org/10.1073/pnas.0904227106CrossRefPubMedPubMedCentral

96.

Park, S. Y., & Nam, J. S. (2020). The force awakens: Metastatic dormant cancer cells. Experimental & Molecular Medicine, 52(4), 569–581.CrossRef

97.

Parker, K. A., Robinson, N. J., & Schiemann, W. P. (2021). The role of RNA processing and regulation in metastatic dormancy. Seminars in Cancer Biology, 78, 23–34. https://doi.org/10.1016/j.semcancer.2021.03.020CrossRefPubMedPubMedCentral

98.

Nobre, A. R., Risson, E., Singh, D. K., Di Martino, J. S., Cheung, J. F., Wang, J., Johnson, J., Russnes, H. G., Bravo-Cordero, J. J., Birbrair, A., & Naume, B. (2021). Bone marrow NG2(+)/Nestin(+) mesenchymal stem cells drive DTC dormancy via TGFbeta2. Nat Cancer, 2(3), 327–339. https://doi.org/10.1038/s43018-021-00179-8CrossRefPubMedPubMedCentral

99.

Linde, N., Casanova-Acebes, M., Sosa, M. S., Mortha, A., Rahman, A., Farias, E., Harper, K., Tardio, E., Reyes Torres, I., Jones, J., & Condeelis, J. (2018). Macrophages orchestrate breast cancer early dissemination and metastasis. Nature Communications, 9(1), 21. https://doi.org/10.1038/s41467-017-02481-5CrossRefPubMedPubMedCentral

100.

Borriello, L., Coste, A., Traub, B., Sharma, V. P., Karagiannis, G. S., Lin, Y., Wang, Y., Ye, X., Duran, C. L., Chen, X., & Friedman, M. (2022). Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells. Nature Communications, 13(1), 626. https://doi.org/10.1038/s41467-022-28076-3CrossRefPubMedPubMedCentral

101.

Lan, Q., Peyvandi, S., Duffey, N., Huang, Y. T., Barras, D., Held, W., Richard, F., Delorenzi, M., Sotiriou, C., Desmedt, C., & Lorusso, G. (2019). Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene, 38(15), 2814–2829. https://doi.org/10.1038/s41388-018-0624-2CrossRefPubMed

102.

Owen, K. L., Gearing, L. J., Zanker, D. J., Brockwell, N. K., Khoo, W. H., Roden, D. L., Cmero, M., Mangiola, S., Hong, M. K., Spurling, A. J., & McDonald, M. (2020). Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 21(6), e50162. https://doi.org/10.15252/embr.202050162CrossRefPubMedPubMedCentral

103.

Yu-Lee, L. Y., Yu, G., Lee, Y. C., Lin, S. C., Pan, J., Pan, T., Yu, K. J., Liu, B., Creighton, C. J., Rodriguez-Canales, J., & Villalobos, P. A. (2018). Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway. Cancer Research, 78(11), 2911–2924. https://doi.org/10.1158/0008-5472.CAN-17-1051CrossRefPubMedPubMedCentral

104.

Barney, L. E., Hall, C. L., Schwartz, A. D., Parks, A. N., Sparages, C., Galarza, S., Platt, M. O., Mercurio, A. M., & Peyton, S. R. (2020). Tumor cell-organized fibronectin maintenance of a dormant breast cancer population. Science Advances, 6(11), eaaz4157. https://doi.org/10.1126/sciadv.aaz4157CrossRefPubMedPubMedCentral

105.

Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., & Gil, J. (2019). Cellular senescence: Defining a path forward. Cell, 179(4), 813–827. https://doi.org/10.1016/j.cell.2019.10.005CrossRefPubMed

106.

Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059CrossRefPubMed

107.

Ruppender, N. S., Morrissey, C., Lange, P. H., & Vessella, R. L. (2013). Dormancy in solid tumors: Implications for prostate cancer. Cancer and Metastasis Reviews, 32, 501–509.CrossRefPubMed

108.

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011). Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science, 331(6024), 1565–1570. https://doi.org/10.1126/science.1203486CrossRefPubMed

109.

Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: Molecular insights and evolving paradigms. Cell, 147(2), 275–292. https://doi.org/10.1016/j.cell.2011.09.024CrossRefPubMedPubMedCentral

110.

Hansel, G., Schonlebe, J., Haroske, G., & Wollina, U. (2010). Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). A single-centre analysis of 1881 patients with a follow-up of 10 years or more. Journal of the European Academy of Dermatology and Venereology, 24(7), 833–836. https://doi.org/10.1111/j.1468-3083.2009.03536.xCrossRefPubMed

111.

Diamantopoulou, Z., Castro-Giner, F., Schwab, F. D., Foerster, C., Saini, M., Budinjas, S., Strittmatter, K., Krol, I., Seifert, B., Heinzelmann-Schwarz, V., & Kurzeder, C. (2022). The metastatic spread of breast cancer accelerates during sleep. Nature, 607(7917), 156–162. https://doi.org/10.1038/s41586-022-04875-yCrossRefPubMed

112.

Fox, D. B., Garcia, N. M., McKinney, B. J., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2020). NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism. Nature Metabolism, 2(4), 318–334. https://doi.org/10.1038/s42255-020-0191-zCrossRefPubMedPubMedCentral

113.

Tivari, S., Lu, H., Dasgupta, T., De Lorenzo, M. S., & Wieder, R. (2018). Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence. Cell Communication and Signaling: CCS, 16(1), 48. https://doi.org/10.1186/s12964-018-0259-5CrossRefPubMedPubMedCentral

114.

Liu, Y., Lv, J., Liang, X., Yin, X., Zhang, L., Chen, D., Jin, X., Fiskesund, R., Tang, K., Ma, J., & Zhang, H. (2018). Fibrin stiffness mediates dormancy of tumor-repopulating cells via a Cdc42-driven Tet2 epigenetic program. Cancer Research, 78(14), 3926–3937. https://doi.org/10.1158/0008-5472.CAN-17-3719CrossRefPubMed

115.

Nasr, M., Farghaly, M., Elsaba, T., El-Mokhtar, M., Radwan, R., Elsabahy, M., Abdelkareem, A., Fakhry, H., & Mousa, N. (2018). Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression. International Journal of Biochemistry and Cell Biology, 105, 84–93. https://doi.org/10.1016/j.biocel.2018.10.005CrossRefPubMed

116.

Wendt, M. K., Taylor, M. A., Schiemann, B. J., & Schiemann, W. P. (2011). Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Molecular Biology of the Cell, 22(14), 2423–2435. https://doi.org/10.1091/mbc.E11-04-0306CrossRefPubMedPubMedCentral

117.

Barkan, D., & Green, J. E. (2011). An in vitro system to study tumor dormancy and the switch to metastatic growth. Journal of Visualized Experiments, 11(54), e2914. https://doi.org/10.3791/2914CrossRef

118.

Vishnoi, M., Peddibhotla, S., Yin, W., Scamardo, A. T., George, G. C., Hong, D. S., & Marchetti, D. (2015). The isolation and characterization of CTC subsets related to breast cancer dormancy. Scientific Reports, 5, 17533. https://doi.org/10.1038/srep17533CrossRefPubMedPubMedCentral

119.

Mauro, C. D., Pesapane, A., Formisano, L., Rosa, R., D’Amato, V., Ciciola, P., Servetto, A., Marciano, R., Orsini, R. C., Monteleone, F., & Zambrano, N. (2017). Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Scientific Reports, 7(1), 9388. https://doi.org/10.1038/s41598-017-10062-1CrossRefPubMedPubMedCentral

120.

Aguirre Ghiso, J. A., Kovalski, K., & Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. The Journal of Cell Biology, 147(1), 89–104. https://doi.org/10.1083/jcb.147.1.89CrossRefPubMed

121.

Allgayer, H., & Aguirre-Ghiso, J. A. (2008). The urokinase receptor (u-PAR)--A link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS, 116(7-8), 602–614. https://doi.org/10.1111/j.1600-0463.2008.00997.xCrossRefPubMedPubMedCentral

122.

Xiao, Q., & Ge, G. (2012). Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenvironment, 5(3), 261–273. https://doi.org/10.1007/s12307-012-0105-zCrossRefPubMedPubMedCentral

123.

Weidenfeld, K., Schif-Zuck, S., Abu-Tayeh, H., Kang, K., Kessler, O., Weissmann, M., Neufeld, G., & Barkan, D. (2016). Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth. Oncotarget, 7(44), 71362–71377. https://doi.org/10.18632/oncotarget.12109CrossRefPubMedPubMedCentral

124.

Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, Hausen AZ, Brunton VG., "The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs," Nature Cell Biology, vol. 11, no. 12, pp. 1487-1495, Dec 2009. https://doi.org/10.1038/ncb1998.

125.

Wang, F., Sun, G., Peng, C., Chen, J., Quan, J., Wu, C., Lian, X., Tang, W., & Xiang, D. (2021). ZEB1 promotes colorectal cancer cell invasion and disease progression by enhanced LOXL2 transcription. International Journal of Clinical and Experimental Pathology, 14(1), 9–23. https://www.ncbi.nlm.nih.gov/pubmed/33532019PubMedPubMedCentral

126.

Kondapaneni, R. V., & Rao, S. S. (2020). Matrix stiffness and cluster size collectively regulate dormancy versus proliferation in brain metastatic breast cancer cell clusters. Biomaterials Science, 8(23), 6637–6646. https://doi.org/10.1039/d0bm00969eCrossRefPubMed

127.

Izraely, S., & Witz, I. P. (2020). Site-specific metastasis: A cooperation between cancer cells and the metastatic microenvironment. International Journal of Cancer, 148(6), 1308–1322. https://doi.org/10.1002/ijc.33247CrossRefPubMedPubMedCentral

128.

S. S. Rao, J. Dejesus, A. R. Short, J. J. Otero, A. Sarkar, and J. O. Winter, "Glioblastoma behaviors in three-dimensional collagen-hyaluronan composite hydrogels," ACS Applied Materials & Interfaces, vol. 5, no. 19, pp. 9276-9284, Oct 9 2013. https://doi.org/10.1021/am402097j.

129.

Jamin, Y., Boult, J. K., Li, J., Popov, S., Garteiser, P., Ulloa, J. L., Cummings, C., Box, G., Eccles, S. A., Jones, C., & Waterton, J. C. (2015). Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography. Cancer Research, 75(7), 1216–1224. https://doi.org/10.1158/0008-5472.CAN-14-1997CrossRefPubMedPubMedCentral

130.

Narkhede, A. A., Crenshaw, J. H., Crossman, D. K., Shevde, L. A., & Rao, S. S. (2020). An in vitro hyaluronic acid hydrogel based platform to model dormancy in brain metastatic breast cancer cells. Acta Biomaterialia, 107, 65–77. https://doi.org/10.1016/j.actbio.2020.02.039CrossRefPubMed

131.

Araujo, A., Cook, L. M., Lynch, C. C., & Basanta, D. (2018). Size matters: Metastatic cluster size and stromal recruitment in the establishment of successful prostate cancer to bone metastases. Bulletin of Mathematical Biology, 80(5), 1046–1058. https://doi.org/10.1007/s11538-018-0416-4CrossRefPubMedPubMedCentral

132.

Peart, T., Valdes, Y. R., Correa, R. J., Fazio, E., Bertrand, M., McGee, J., Prefontaine, M., Sugimoto, A., DiMattia, G. E., & Shepherd, T. G. (2015). Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids. Oncotarget, 6(26), 22424–22438. https://doi.org/10.18632/oncotarget.4211CrossRefPubMedPubMedCentral

133.

Shackelford, D. B., & Shaw, R. J. (2009). The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nature Reviews. Cancer, 9(8), 563–575. https://doi.org/10.1038/nrc2676CrossRefPubMedPubMedCentral

134.

Tanwar, P. S., Mohapatra, G., Chiang, S., Engler, D. A., Zhang, L., Kaneko-Tarui, T., Ohguchi, Y., Birrer, M. J., & Teixeira, J. M. (2014). Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis, 35(3), 546–553. https://doi.org/10.1093/carcin/bgt357CrossRefPubMed

135.

Mihaylova, M. M., & Shaw, R. J. (2011). The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biology, 13(9), 1016–1023. https://doi.org/10.1038/ncb2329CrossRefPubMedPubMedCentral

136.

Hampsch, R. A., Wells, J. D., Traphagen, N. A., CF, M. C., Fields, J. L., Shee, K., Dillon, L. M., Pooler, D. B., Lewis, L. D., Demidenko, E., & Huang, Y. H. (2020). AMPK activation by metformin promotes survival of dormant ER(+) breast cancer cells. Clinical Cancer Research, 26(14), 3707–3719. https://doi.org/10.1158/1078-0432.CCR-20-0269CrossRefPubMedPubMedCentral

137.

Wu, S., Lu, H., & Bai, Y. (2019). Nrf2 in cancers: A double-edged sword. Cancer Medicine, 8(5), 2252–2267. https://doi.org/10.1002/cam4.2101CrossRefPubMedPubMedCentral

138.

Fox, D. B., Garcia, N. M., BJ, M. K., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2020). NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism. Nature Metabolism, 2, 318–334. https://doi.org/10.1038/s42255-020-0191-zCrossRefPubMedPubMedCentral

139.

Sosa, M. S., Parikh, F., Maia, A. G., Estrada, Y., Bosch, A., Bragado, P., Ekpin, E., George, A., Zheng, Y., Lam, H. M., & Morrissey, C. (2015). NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nature Communications, 6(1), 1–14. https://doi.org/10.1038/ncomms7170CrossRef

140.

Francescangeli, F., Contavalli, P., De Angelis, M. L., Careccia, S., Signore, M., Haas, T. L., Salaris, F., Baiocchi, M., Boe, A., Giuliani, A., & Tcheremenskaia, O. (2020). A pre-existing population of ZEB2(+) quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. Journal of Experimental & Clinical Cancer Research, 39(1), 2. https://doi.org/10.1186/s13046-019-1505-4CrossRef

141.

Malladi, S., Macalinao, D. G., Jin, X., He, L., Basnet, H., Zou, Y., De Stanchina, E., & Massagué, J. (2016). Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell, 165(1), 45–60. https://doi.org/10.1016/j.cell.2016.02.025CrossRefPubMedPubMedCentral

142.

Aguirre-Ghiso, J., Nobre, A. R., Dalla, E., Yang, J., Huang, X., Kenigsberg, E., & Wang, J. (2021). A mesenchymal-like program of dormancy controlled by ZFP281 serves as a barrier to metastatic progression of early disseminated cancer cells. Research Square. https://doi.org/10.21203/rs.3.rs-145308/v1CrossRef

143.

Khalil, B. D., Sanchez, R., Rahman, T., Rodriguez-Tirado, C., Moritsch, S., Martinez, A. R., Miles, B., Farias, E., Mezei, M., Nobre, A. R., & Singh, D. (2022). An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. The Journal of Experimental Medicine, 219(1). https://doi.org/10.1084/jem.20210836

144.

Li, Y., Hu, H., Wang, Y., Fan, Y., Yang, Y., Guo, B., Xie, X., Lian, J., Jiang, B., Han, B., & Wang, Y. (2020). CUL4B contributes to cancer stemness by repressing tumor suppressor miR34a in colorectal cancer. Oncogenesis, 9(2), 20. https://doi.org/10.1038/s41389-020-0206-3CrossRefPubMedPubMedCentral

145.

Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009). Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Research, 11(4), R46. https://doi.org/10.1186/bcr2333CrossRefPubMedPubMedCentral

146.

Thangavel, H., Angelis, C. D., Vasaikar, S., Bhat, R., Jolly, M. K., Nagi, C., Creighton, C. J., Chen, F., Dobrolecki, L. E., George, J. T., & Kumar, T. (2019). A CTC-cluster-specific signature derived from OMICS analysis of patient-derived xenograft tumors predicts outcomes in basal-like breast cancer. Journal of Clinical Medicine, 8(11). https://doi.org/10.3390/jcm8111772

147.

Kapeleris, J., Zou, H., Qi, Y., Gu, Y., Li, J., Schoning, J., Monteiro, M. J., & Gu, W. (2020). Cancer stemness contributes to cluster formation of colon cancer cells and high metastatic potentials. Clinical and Experimental Pharmacology & Physiology, 47(5), 838–847. https://doi.org/10.1111/1440-1681.13247CrossRef

148.

Ring, A., Nguyen-Strauli, B. D., Wicki, A., & Aceto, N. (2023). Biology, vulnerabilities and clinical applications of circulating tumour cells. Nature Reviews. Cancer, 23(2), 95–111. https://doi.org/10.1038/s41568-022-00536-4CrossRefPubMed

At a glance: The STEP trials

Springer Medicine

How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

Epigenetic control of pancreatic cancer metastasis

Update on carcinoma of unknown primary for histopathologists

Metastasis suppressor genes and their role in the tumor microenvironment

Mechanisms of action of NME metastasis suppressors – a family affair

Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response

Metastasis suppressors: a paradigm shift in cancer biology

Keynote webinar | Spotlight on antibody–drug conjugates in cancer